Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/bph.16252
Keywords
biomarkers; drug resistance; renal cell carcinoma; sunitinib; treatment strategies
Categories
Ask authors/readers for more resources
This review summarizes the mechanisms of sunitinib resistance in renal cell carcinoma, including activation of bypass or alternative pathways, inadequate drug accumulation, tumor microenvironment, metabolic reprogramming, and epigenetic regulation. It also covers current and potential biomarkers as well as treatment strategies for overcoming sunitinib resistance.
Sunitinib is the first-line drug for renal cell carcinoma (RCC) treatment. However, patients who received sunitinib treatment will ultimately develop drug resistance after 6-15 months, creating a huge obstacle to the current treatment of renal cell carcinoma. Therefore, it is urgent to clarify the mechanisms of sunitinib resistance and develop new strategies to overcome it. In this review, the mechanisms of sunitinib resistance in renal cell carcinoma have been summarized based on five topics: activation of bypass or alternative pathway, inadequate drug accumulation, tumour microenvironment, metabolic reprogramming and epigenetic regulation. Furthermore, present and potential biomarkers, as well as potential treatment strategies for overcoming sunitinib resistance in renal cell carcinoma, are also covered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available